BioCentury
ARTICLE | Clinical News

EC approves Amgen's biosimilar Avastin

January 19, 2018 7:36 PM UTC

Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said the European Commission approved Mvasi (ABP 215), a biosimilar of Avastin bevacizumab. The approval includes all cancer types on Avastin's EU label -- non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and colorectal, breast, ovarian and cervical cancers.

Amgen said the approval is the EC's first for a biosimilar of Avastin. The company declined to provide a launch date or pricing details...